BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas

BMX-001 作为治疗高级别胶质瘤的治疗剂

基本信息

  • 批准号:
    8904217
  • 负责人:
  • 金额:
    $ 97.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-18 至 2017-08-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Phase 1 and Phase 2 clinical trials of a new class of redox-active pharmaceutical are proposed in high-grade glioma (WHO grade III and IV). This project will test a compound that crosses the blood-brain barrier and which prevents hippocampal stem cell loss and white matter degradation following radiation therapy (RT). The compound also inhibits tumor regrowth following RT and thus has the dual impact of protecting normal tissues while improving tumor treatment responses. This drug is both neuroprotective against RT and a radio sensitizer that is expected to enhance inhibition of glioblastoma by RT. Primary brain tumors represent 1% of all diagnosed cancers. Even though these tumors represent a rare malignancy, high-grade gliomas are aggressive and lethal and are associated with severe disabling central nervous system involvement. Cognition and neurological function are compromised at diagnosis and during treatment. The standard of care for newly diagnosed high-grade gliomas involves surgical resection, followed by RT with concurrent temozolomide (TMZ). Despite aggressive treatment, nearly all patients with the most common form of adult primary brain tumor, glioblastoma (WHO grade IV), die of disease progression; median survival is 9-15 months after diagnosis. Most high-grade gliomas are resistant to current available therapies. Thus, a major requirement for the next generation therapy of primary brain tumors requires more effective tumor control and protection against the neurotoxicity. The objective of this proposed project is to test the hypothesis that a new class of redox-active metalloporphyrins is an effective radio protector and tumor sensitizer in brain tissue. The specific aims are to: 1) perform a Phase 1 clinical trial of this new drug in combination with standard RT and TMZ in newly diagnosed high-grade glioma patients, and 2) perform a randomized open-label Phase 2 clinical trial of the new drug in combination with standard RT and TMZ versus standard RT and TMZ alone in patients with newly diagnosed high-grade glioma patients. The primary outcome is protection/improvement of cognition. This new class of drug has the potential to protect against deterioration of cognition and improve health-related quality of life in high-grade glioma patients undergoing RT and chemotherapy, while also enhancing patient survival.
 描述(由申请人提供):拟在高级别胶质瘤(WHO III级和IV级)中进行一类新的氧化还原活性药物的I期和II期临床试验。该项目将测试一种化合物,该化合物可以穿过血脑屏障,防止放射治疗(RT)后海马干细胞丢失和白色物质降解。该化合物还抑制RT后的肿瘤再生长,因此具有保护正常组织同时改善肿瘤治疗反应的双重影响。这种药物既对RT具有神经保护作用,又是一种放射增敏剂,有望增强RT对胶质母细胞瘤的抑制作用。原发性脑肿瘤占所有诊断癌症的1%。尽管这些肿瘤是一种罕见的恶性肿瘤,但高级别胶质瘤具有侵袭性和致命性,并伴有严重的中枢神经系统受累。认知和神经功能在诊断和治疗期间受到损害。新诊断的高级别胶质瘤的标准治疗包括手术切除,然后进行RT和同时进行替莫唑胺(TMZ)。尽管进行了积极的治疗,但几乎所有最常见的成人原发性脑肿瘤-胶质母细胞瘤(WHO IV级)患者都死于疾病进展;诊断后的中位生存期为9-15个月。大多数高级别神经胶质瘤对目前可用的疗法具有抗性。因此,原发性脑肿瘤的下一代治疗的主要要求是需要更有效的肿瘤控制和针对神经毒性的保护。本项目的目的是验证一种新的氧化还原活性金属卟啉是脑组织中有效的放射保护剂和肿瘤增敏剂的假设。具体目标是:1)在新诊断的高级别胶质瘤患者中进行该新药与标准RT和TMZ组合的I期临床试验,以及2)在新诊断的高级别胶质瘤患者中进行该新药与标准RT和TMZ组合对比标准RT和TMZ单独的随机开放标签II期临床试验。主要结局是保护/改善认知。这种新型药物有可能防止高级胶质瘤患者的认知恶化并改善健康相关的生活质量 接受RT和化疗,同时也提高了患者的生存率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James D Crapo其他文献

James D Crapo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James D Crapo', 18)}}的其他基金

COPD(GENE): TASK B: "STEWARDSHIP OF BIOSPECIMEN AND DATA REPOSITORIES"
COPD(基因):任务 B:“生物样本和数据存储库的管理”
  • 批准号:
    10974167
  • 财政年份:
    2023
  • 资助金额:
    $ 97.64万
  • 项目类别:
GENETIC EPIDEMIOLOGY OF COPD (COPD GENE) TASK A: STUDY VISIT 4, COLLECTION OF COPDGENE STUDY DATA ANDBIOSPECIMENS AND OVERSIGHT OF THE COPDGENE STUDY
COPD 的遗传流行病学(COPD 基因) 任务 A:研究访问 4、收集 COPDGENE 研究数据和生物样本以及 COPDGENE 研究的监督
  • 批准号:
    10974166
  • 财政年份:
    2023
  • 资助金额:
    $ 97.64万
  • 项目类别:
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas
BMX-001 作为治疗高级别胶质瘤的治疗剂
  • 批准号:
    10603182
  • 财政年份:
    2015
  • 资助金额:
    $ 97.64万
  • 项目类别:
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas
BMX-001 作为治疗高级别胶质瘤的治疗剂
  • 批准号:
    9145170
  • 财政年份:
    2015
  • 资助金额:
    $ 97.64万
  • 项目类别:
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas
BMX-001 作为治疗高级别胶质瘤的治疗剂
  • 批准号:
    10170294
  • 财政年份:
    2015
  • 资助金额:
    $ 97.64万
  • 项目类别:
Building Consensus on Qualitative Chest CT-based Subphenotypes for COPD
就慢性阻塞性肺病基于胸部 CT 的定性亚表型建立共识
  • 批准号:
    7915158
  • 财政年份:
    2010
  • 资助金额:
    $ 97.64万
  • 项目类别:
TREATMENT OF BPD USING MIMETICS OF SUPEROXIDE DISMUTASE
使用超氧化物歧化酶模拟物治疗 BPD
  • 批准号:
    7716049
  • 财政年份:
    2008
  • 资助金额:
    $ 97.64万
  • 项目类别:
Genetic Epidemiology of COPD
慢性阻塞性肺病的遗传流行病学
  • 批准号:
    7436948
  • 财政年份:
    2007
  • 资助金额:
    $ 97.64万
  • 项目类别:
Genetic Epidemiology of COPD
慢性阻塞性肺病的遗传流行病学
  • 批准号:
    7663132
  • 财政年份:
    2007
  • 资助金额:
    $ 97.64万
  • 项目类别:
(1 of 2) Genetic Epidemiology of COPD
(1 of 2) COPD 的遗传流行病学
  • 批准号:
    8371837
  • 财政年份:
    2007
  • 资助金额:
    $ 97.64万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 97.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了